Références Scientifiques Consultez la littérature scientifique qui soutient nos cibles moléculaires et notre approche létale synthétique. octobre 2025 Preliminary safety and antitumor activity of RP-1664, a first-in-class PLK4 inhibitor, as monotherapy in advanced solid tumors with and without TRIM37 amplification Benjamin Herzberg, Et Al. The 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics octobre 2025 Abstract: Preliminary safety and antitumor activity of RP-1664, a first-in-class PLK4 inhibitor, as monotherapy in advanced solid tumors with and without TRIM37 amplification Benjamin Herzberg, Et Al. 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics mai 2025 Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 Inhibitor Vallée Et Al. Journal of Medicinal Chemistry avril 2025 Update on the overall safety and efficacy of the combination PKMYT1 inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase 1 MYTHIC study (NCT04855656) Schram et al. AACR 2025 février 2025 A dual mechanism of sensitivity to PLK4 inhibition by RP-1664 in neuroblastoma Isabel Soria-Bretones, Matias Casas-Selves, Et Al. bioRxiv octobre 2024 Individualized schedule improves rates and severity of anemia in patients treated with lunresertib, a PKMYT1 inhibitor, and camonsertib, an ATR inhibitor, in the Phase I MYTHIC study Højgaard Et Al. ENA 2024 septembre 2024 Genotypically-selected pan cancer trial of camonsertib with palliative radiation in the treatment of metastatic tumors harboring an ataxia-telangiectasia mutated (ATM) mutation Nancy Lee, Et Al. ASTRO 2024 septembre 2024 Driver alterations in FBXW7, PPP2R1A, CCNE1 confer a poor prognosis in patients with metastatic gynecologic cancers Alison M. Schram, Et Al. AACR Ovarian Research Symposium 2024 septembre 2024 Camonsertib (cam) monotherapy in patients (pts) with advanced cancers harboring ATM loss-of-function (LoF) Benedito A. Carneiro, Et Al. ESMO Congress 2024 août 2024 Low Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer Mi Li, Et Al. Cancer Research, August 26 2024 12345 Notre pipeline comprend plusieurs programmes de développement. Voir Notre Pipeline
